Goodwin Procter advised Bio Products Laboratory and Tiancheng International Investment Limited on the deal. The shareholders of Kedrion was advised by Carnelutti and Pedersoli Studio Legale, […]
Permira’s Investment in BPL and Kedrion
CareMetx’s Acquisition of Human Care Systems
Goodwin Procter advised Human Care Systems on the deal. Human Care Systems, Inc. announced its sale to CareMetx, LLC. Human Care Systems is a company focused on […]
Aldrich Capital Partners’ Acquisition of Compliancy Group
Goodwin advised Aldrich Capital Partners on the deal. Aldrich Capital Partners announced its acquisition of Compliancy Group, LLC. Aldrich is a growth equity firm supporting disruptive innovation […]
Aldrich Capital Partners’ Acquisition of PRIA Healthcare Management
Goodwin Procter advised Aldrich Capital Partners on the deal. Aldrich Capital Partners announced its acquisition of PRIA Healthcare Management. Aldrich is a growth equity firm supporting disruptive […]
Exscientia’s $510.4 Million IPO
Cooley LLP advised Exscientia on the deal while Goodwin Procter represented Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities and Barclays Capital […]
EQRx’s Merger with CM Life Sciences III
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM […]
Pfizer’s $2.26 Billion Acquisition of Trillium Therapeutics
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX: […]
Centessa Pharmaceuticals’ $330 Million IPO
Wilson Sonsini Goodrich & Rosati and Goodwin Procter LLP advised Centessa Pharmaceuticals on the deal. Centessa Pharmaceuticals, a clinical-stage company employing its innovative asset-centric business model […]
Amryt Pharma’s Acquisition of Chiasma
Goodwin Procter LLP advised Chiasma, Inc. on the deal. Chiasma, Inc. (Nasdaq: CHMA) announced its definitive agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM: […]
Vascular Biogenics Ltd.’s $28.3 Million Shares Offering
Goodwin Procter LLP advised Vascular Biogenics Ltd. on the deal. Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT) announced the closing of its underwritten public offering […]
Cerevel Therapeutics’ $125 Million Non-dilutive Financing Transaction for Tavapadon
Goodwin Procter LLP advised Cerevel Therapeutics on the deal. Ropes & Gray represented Bain Capital, while Wyrick Robbins Yates & Ponton LLP acted as legal counsel […]
Better Therapeutics’ $187 Million Merger Agreement with Mountain Crest Acquisition Corp II
Goodwin Procter LLP advised Better Therapeutics, Inc. on the deal. Better Therapeutics, Inc. announced its definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD;), a […]